Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease. - Test2 - elhamkhani - TriplyDB

Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.

Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.

http://www.wikidata.org/entity/Q33626787

about

Enzyme activities of α-glucosidase in Japanese neonates with pseudodeficiency alleles Moonlighting newborn screening markers: the incidental discovery of a second-tier test for Pompe disease.

P2860

Q33889736-AFB3B9AD-2710-451A-BCB1-8117F8F7B94B Q52820616-E4731E56-7A5D-44A8-BF40-196F38819E55

P2860

Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.

http://www.wikidata.org/entity/Q33626787

description

2017 nî lūn-bûn

@nan

2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Liquid Chromatography-Tandem M ...... g Evaluation of Pompe Disease.

@ast

Liquid Chromatography-Tandem M ...... g Evaluation of Pompe Disease.

@en

type

label

Liquid Chromatography-Tandem M ...... g Evaluation of Pompe Disease.

@ast

Liquid Chromatography-Tandem M ...... g Evaluation of Pompe Disease.

@en

prefLabel

Liquid Chromatography-Tandem M ...... g Evaluation of Pompe Disease.

@ast

Liquid Chromatography-Tandem M ...... g Evaluation of Pompe Disease.

@en

P1433

Q33626787-6FF5A436-7B1D-40B6-ABD0-A41DD30F9E7A

P1476

Q33626787-85298B3A-95EE-41EC-93EB-E5EB0E5F8065

P2093

Q33626787-08832F4A-47F6-4B61-BA58-E04E1A08443B

Q33626787-0AB40B25-E88A-4FBC-95E6-65303FE0BC78

Q33626787-1480698F-C3EA-40E4-B8C8-9B698195CCC0

Q33626787-212C6BCD-2D1D-4711-8594-6BE0D5601C30

Q33626787-3B22FECB-461B-4480-8D9A-AE400CC5B924

Q33626787-3F05DBE3-EA86-4DB9-BAFD-FBA46A6BFA4D

Q33626787-402BDA41-D822-4BBB-967C-0A9BF7B5F138

Q33626787-5FC5A408-5552-4CE7-9A51-7E725CC9225F

Q33626787-7C3F660F-2467-4FEC-B877-B3F306EECF1B

Q33626787-7F7C35CC-FF28-49EC-A7D7-7DFC3C5DC35F

P2860

Q33626787-061924D1-9839-413C-9654-D0820C576A82

Q33626787-1266C13E-8D8D-40F2-A276-9842A3BE3FDE

Q33626787-1D94B705-5E91-4C86-84A0-AE5698548551

Q33626787-1E992790-6CA2-4127-B328-09B6DC5607ED

Q33626787-33C254DF-81BA-42F7-95BB-BF9CB9F40232

Q33626787-47451188-92F4-4F79-9F04-CCCC82FF9A1D

Q33626787-47EE97C1-0BE6-4BEC-9BED-CC0D17E73206

Q33626787-497CF5CB-90E5-48E9-9E17-39557E8E2BD9

Q33626787-4B824D69-0D8B-43A7-B19D-A0ED2565F485

Q33626787-5CB66AD1-39FA-4526-8D59-82777CA026B2

P304

Q33626787-5747436D-7ECB-43F9-B308-58C1A931B158

P31

Q33626787-5962C3B4-88AA-4E9E-8C3D-D6D6CED5E224

P356

Q33626787-AC52CE87-4263-4478-A39D-88092C4DB7D1

P407

Q33626787-8F3E709F-E915-4929-B30D-43C6989B5C22

P433

Q33626787-B2CCD6F3-E703-4DF0-BE87-DDE5574140E5

P478

Q33626787-32412A52-640B-4DAC-9442-849B4CC81091

P577

Q33626787-68ACA272-8A6B-4934-8D7C-E829C9684DF9

P698

Q33626787-A06EC676-C4FF-4E3C-909A-EC144C278659

P932

Q33626787-82014414-A87A-49B2-A525-4CDAD43FB415

P356

CLINCHEM.2016.259036

P1433

Clinical Chemistry

P1476

Liquid Chromatography-Tandem M ...... g Evaluation of Pompe Disease.

@en

P2093

Arun Babu Kumar

http://www.w3.org/2001/XMLSchema#string

Chunli Yu

http://www.w3.org/2001/XMLSchema#string

Colleen Stevens

http://www.w3.org/2001/XMLSchema#string

Erin E Hughes

http://www.w3.org/2001/XMLSchema#string

Farideh Ghomashchi

http://www.w3.org/2001/XMLSchema#string

Hsuan Chieh Liao

http://www.w3.org/2001/XMLSchema#string

Hui Zhou

http://www.w3.org/2001/XMLSchema#string

Jingyu Huang

http://www.w3.org/2001/XMLSchema#string

Joseph J Orsini

http://www.w3.org/2001/XMLSchema#string

Lisa DiAntonio

http://www.w3.org/2001/XMLSchema#string

P2860

Multiplex newborn screening for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases using a digital microfluidic platform.

Methods of diagnosis of patients with Pompe disease: Data from the Pompe Registry.

Pompe disease diagnosis and management guideline.

Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.

Pompe disease in infants: improving the prognosis by newborn screening and early treatment.

Baseline Urinary Glucose Tetrasaccharide Concentrations in Patients with Infantile- and Late-Onset Pompe Disease Identified by Newborn Screening

Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening.

Tandem Mass Spectrometry Has a Larger Analytical Range than Fluorescence Assays of Lysosomal Enzymes: Application to Newborn Screening and Diagnosis of Mucopolysaccharidoses Types II, IVA, and VI.

Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.

Pompe disease: early diagnosis and early treatment make a difference.

P304

842-851

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1373/CLINCHEM.2016.259036

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28196920

http://www.w3.org/2001/XMLSchema#string

P932

5413112

http://www.w3.org/2001/XMLSchema#string